Back to Search
Start Over
Eslicarbazepine acetate in post-stroke epilepsy: Clinical practice evidence from Euro-Esli.
- Source :
-
Acta neurologica Scandinavica [Acta Neurol Scand] 2020 Dec; Vol. 142 (6), pp. 563-573. Date of Electronic Publication: 2020 Aug 12. - Publication Year :
- 2020
-
Abstract
- Objectives: To assess the effectiveness and safety/tolerability of eslicarbazepine acetate (ESL) in patients included in the Euro-Esli study who had focal seizures associated with post-stroke epilepsy (PSE).<br />Materials and Methods: Euro-Esli was a pooled analysis of 14 European clinical practice studies. Effectiveness assessments (evaluated after 3, 6 and 12 months of ESL treatment and at final follow-up ["last visit"]) included rates of response (≥50% seizure frequency reduction), seizure freedom (no seizures since at least the prior visit) and retention. Safety/tolerability was assessed throughout ESL treatment by evaluating adverse events (AEs) and discontinuation due to AEs. A post hoc analysis was conducted of patients with PSE versus patients without PSE ("non-PSE").<br />Results: Of 1656 patients included in the analysis, 76 (4.6%) had PSE and 1580 (95.4%) had non-PSE. Compared with non-PSE patients, PSE patients were significantly older, had significantly shorter epilepsy duration, significantly lower total baseline seizure frequency, and were treated with significantly fewer prior and concomitant antiepileptic drugs (P < .001 for all). At the last visit, the responder rate was significantly higher in PSE versus non-PSE patients (72.9% vs 60.6%; P = .040), as was the seizure freedom rate (48.6% vs 31.7%; P = .003). After 12 months, retention was significantly higher in PSE versus non-PSE patients (87.8% vs 77.4%; P = .035). The incidence of AEs was similar for PSE versus non-PSE patients (36.0% vs 35.8%; P = .966).<br />Conclusions: These findings suggest that ESL may be an effective and well-tolerated treatment option for patients with focal seizures due to PSE.<br /> (© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Subjects :
- Adolescent
Adult
Aged
Aged, 80 and over
Anticonvulsants adverse effects
Dibenzazepines adverse effects
Female
Humans
Male
Middle Aged
Seizures prevention & control
Treatment Outcome
Young Adult
Anticonvulsants therapeutic use
Dibenzazepines therapeutic use
Epilepsy drug therapy
Epilepsy etiology
Stroke complications
Subjects
Details
- Language :
- English
- ISSN :
- 1600-0404
- Volume :
- 142
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Acta neurologica Scandinavica
- Publication Type :
- Academic Journal
- Accession number :
- 32691850
- Full Text :
- https://doi.org/10.1111/ane.13323